January 23, 2023
Video
“So many patients with prostate cancer qualify for genetic testing, but it's currently underutilized,” says Stacy Loeb, MD, MSc.
January 17, 2023
“We don’t want to subject patients to a therapeutic strategy that they are unlikely to benefit from,” says Atish D. Choudhury, MD, PhD.
January 06, 2023
“It really was a multidisciplinary effort to pull the data together [and] provide the clinical implications [of] the genetic markers,” says Veda N. Giri, MD.
January 03, 2023
Article
Here is some of the top content on genomic testing from the past year.
December 19, 2022
Tanya Dorff, MD, explains how the next frontier in mCSPC will be the ability to select patients for treatment based more on molecular stratification and not only on disease volume or metachronous vs synchronous presentation.
December 13, 2022
The study found pathogenic or likely pathogenic variants in DNA damage repair genes and HOXB13 to be more frequently observed in Black men with a family history of cancer.
December 12, 2022
UriFind uses a urine sample to assess whether a patient has bladder cancer, avoiding an invasive cystoscopy.
December 09, 2022
“At this time, there are at least 2 classes of therapeutic agents which are used for patients with certain germline or somatic genetic mutations,” says Emmanuel S. Antonarakis, MD.
HIF-2α inhibitors, such as belzutifan (Welireg), are a promising new class of agents emerging in the renal cell carcinoma treatment paradigm, explains Eric Jonasch, MD.
December 08, 2022
“Many urologists in large group practices are doing genetic testing, especially for their high-risk patients,” says Emmanuel S. Antonarakis, MD.
